This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.
Otherwise, enjoy the column!
Subscribe to the Monster Stock Market Commentary and join the 2,365 subscribers getting it for FREE every day!
Michael Kramer own Cisco, Apple, Netflix
Michael Kramer owns IWM Calls
Strange price action today all around the market place, and very tough to understand, even for a seasoned guy like myself. Health care and small-cap stocks were rocked, with the XBI biotech index falling a stunning 4.7%. Meanwhile, the Russell fell 0.92%. The type of decline in the biotech group would have made you think the NASDAQ was down big, but it was flat on the day.
It seems like everyone is freaking out again over drug pricing. This is at the very least a 4-year-old story, and what has changed beside nothing? Well, nothing. This is a political thing that gets thrown around every four years and draws lots of headlines, but nothing changes it would seem. Remember it was in 2015 that Hillary Clinton started the great biotech sell-off when she first mentioned drug pricing.
THANK YOU FOR MAKING MARCH THE MOST SUCCESSFUL MONTH EVER FOR THE MONSTER STOCK MARKET COMMENTARY WITH OVER 80,000 PAGEVIEWS AND COUNTING…
Whether drug pricing changes actually happen is up in the air, but the fear that investors have is very much real, as demonstrated by the market’s reaction. Through in Medicare for all talk and well you get the big sell-off. Let this chart below show you how much damage could be done just on worries.
Can biotech’s and healthcare stocks fall further, sure. I suspect that will settle down at some point. The chart above shows that RSI is has trended lower for a long time, and there are signs of trying to reverse that trend. As long as the XBI can hold $85, and that uptrend in the RSI remains intact, this will merely be a short-term pullback. If that trend in the RSI breaks, and XBI falls below $82, it could get gruesome.
The Russell fell hard today too, but it was encouraging to see it hold support at 1,565. As long as that holds, I think the Russell is ok also.
Netflix gave back its morning gains to finish the day down $5, not a big deal. I don’t see anything wrong with this company, and after doing some further work today, I think the second quarter may prove to be better than guidance. Netflix: Likely Sand Bagged Guidance
The chart is a mess, and I can’t make heads or tails of it anymore. For now, I will stick with my view of the stock rising to $380.
My biggest fear is that this Netflix subscriber stuff and pending “competition” narrative starts to sound like the Tesla Model 3 drama. Because honestly, I won’t make it. I won’t be able to handle the mountains out of mole holes the media will make out of it. I can’t.
From the looks, it may be heading that way. Let hope for the sake of our sanity; it doesn’t.
It looks like Apple broke out today. I mentioned in my ST room yesterday that it had looked there was bullish flag forming.
Today I wrote an article on why I thought Cisco might rise to price not seen in 20 years to around $62. Cisco’s Stock May Reach Prices Not Seen In 20 Years
Citigroup continues to rise as well and looks to be heading towards $73.
Eli Lilly (LLY)
Lilly continues to struggle, and a break below $115 sends the stock back to $104.
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future results.